AI could predict multiple myeloma outcomes using existing patient data

NCT ID NCT07283224

Recruiting now Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at data already collected from 600 multiple myeloma patients to find patterns linking genetics, imaging, and clinical outcomes. Researchers will use artificial intelligence to build models that might predict disease progression and treatment response. No new tests or visits are needed—only existing information is analyzed. The goal is to improve future care without any extra burden on patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to predict how multiple myeloma will progress and how patients will respond to treatment, helping doctors personalize care.
What could go wrong: This is an early-stage data analysis study, not a treatment trial. The AI models may not prove accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

IRCCS AOU Policlinico Sant'Orsola
RECRUITING

Bologna, Bo, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.